- Home
- MIST vs PAVS Comparison
MIST vs PAVS Comparison
Compare MIST & PAVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIST
- PAVS
- Stock Information
- Founded
- MIST 2003
- PAVS 2004
- Country
- MIST Canada
- PAVS United States
- Employees
- MIST N/A
- PAVS N/A
- Industry
- MIST Biotechnology: Pharmaceutical Preparations
- PAVS Medicinal Chemicals and Botanical Products
- Sector
- MIST Health Care
- PAVS Health Care
- Exchange
- MIST Nasdaq
- PAVS Nasdaq
- Market Cap
- MIST 100.3M
- PAVS 88.9M
- IPO Year
- MIST N/A
- PAVS 2019
- Fundamental
- Price
- MIST $1.98
- PAVS $1.34
- Analyst Decision
- MIST Strong Buy
- PAVS
- Analyst Count
- MIST 3
- PAVS 0
- Target Price
- MIST $13.00
- PAVS N/A
- AVG Volume (30 Days)
- MIST 636.8K
- PAVS 103.9K
- Earning Date
- MIST 11-12-2024
- PAVS 08-01-2024
- Dividend Yield
- MIST N/A
- PAVS N/A
- EPS Growth
- MIST N/A
- PAVS N/A
- EPS
- MIST N/A
- PAVS N/A
- Revenue
- MIST N/A
- PAVS $6,544,819.00
- Revenue This Year
- MIST N/A
- PAVS N/A
- Revenue Next Year
- MIST N/A
- PAVS N/A
- P/E Ratio
- MIST N/A
- PAVS N/A
- Revenue Growth
- MIST N/A
- PAVS N/A
- 52 Week Low
- MIST $1.12
- PAVS $0.32
- 52 Week High
- MIST $2.75
- PAVS $2.81
- Technical
- Relative Strength Index (RSI)
- MIST 49.21
- PAVS 62.00
- Support Level
- MIST $1.92
- PAVS $1.27
- Resistance Level
- MIST $2.07
- PAVS $1.39
- Average True Range (ATR)
- MIST 0.20
- PAVS 0.09
- MACD
- MIST -0.03
- PAVS -0.01
- Stochastic Oscillator
- MIST 9.41
- PAVS 48.00
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
About PAVS Paranovus Entertainment Technology Ltd.
Paranovus Entertainment Technology Ltd through its subsidiary, is engaged in the AI-powered entertainment industry, aiming to provide users with AI-driven games and applications to deliver immersive and engaging entertainment experiences. It is planning to launch SimTwin application which will allow users to interact with digital versions of people and capture life moments. The company also has a software development agreement with Blueline Studios Inc which is developing 10,000 Lives, a mobile game where players pursue various careers and life goals using a board game mechanic.